Payment overview · 2025
General Payments
$371.75
5 reported records · 4 companies
Healthcare provider profile · identity verified
Sunil Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEWARK, NJ · NPI 1134256936
Verified facts
What the public records show
CMS Open Payments records show Sunil Patel, M.D. received $371.75 in general payments during 2025 across 5 reported records.
TG Therapeutics, Inc. accounted for 77.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Fiasp by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $286.97 | 77.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.39 | 12.8% | 2 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $18.98 | 5.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.41 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $286.97 | 1 |
| Food and Beverage | $84.78 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $286.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.39 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.39 | 2 | 2025 |
Source payment records
|
|||||
| V.A.C.ULTA Normalized: v a c ulta |
Device | Solventum Corporation | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 978 | 121 |
| Gabapentin | Gabapentin | 348 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 340 | 49 |
| Mirtazapine | Mirtazapine | 313 | 43 |
| Eliquis | Apixaban | 310 | 34 |
| Divalproex Sodium | Divalproex Sodium | 287 | 31 |
| Lisinopril | Lisinopril | 286 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 41 |
| Carvedilol | Carvedilol | 261 | 42 |
| Levetiracetam | Levetiracetam | 232 | 26 |
| Losartan Potassium | Losartan Potassium | 226 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 225 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 194 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 187 | 28 |
| Trazodone Hcl | Trazodone Hcl | 174 | 21 |
| Donepezil Hcl | Donepezil Hcl | 169 | 17 |
| Furosemide | Furosemide | 148 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 148 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 24 |
| Simvastatin | Simvastatin | 137 | 16 |
| Xarelto | Rivaroxaban | 137 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 20 |
| Latanoprost | Latanoprost | 126 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 124 | 13 |
| Entresto | Sacubitril/Valsartan | 122 | 11 |
| Jardiance | Empagliflozin | 115 | suppressed |
| Metformin Hcl | Metformin Hcl | 115 | 18 |
| Nifedipine Er | Nifedipine | 115 | 26 |
| Sertraline Hcl | Sertraline Hcl | 112 | 12 |
| Risperidone | Risperidone | 106 | 11 |
| Haloperidol | Haloperidol | 103 | suppressed |
| Lactulose | Lactulose | 102 | 18 |
| Aripiprazole | Aripiprazole | 100 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 94 | 14 |
| Januvia | Sitagliptin Phosphate | 93 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 11 |
| Memantine Hcl | Memantine Hcl | 87 | 12 |
| Spironolactone | Spironolactone | 86 | 13 |
| Famotidine | Famotidine | 79 | 16 |
| Buspirone Hcl | Buspirone Hcl | 78 | suppressed |
| Omeprazole | Omeprazole | 74 | 13 |
| Midodrine Hcl | Midodrine Hcl | 73 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 70 | 21 |
| Olanzapine | Olanzapine | 70 | suppressed |
| Enulose | Lactulose | 61 | suppressed |
| Insulin Lispro | Insulin Lispro | 58 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 57 | 19 |
| Humalog | Insulin Lispro | 56 | 15 |
| Potassium Chloride | Potassium Chloride | 55 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Baclofen | Baclofen | 49 | suppressed |
| Lacosamide | Lacosamide | 49 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 26 |
| Clonidine Hcl | Clonidine Hcl | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 12 |
| Ibuprofen | Ibuprofen | 44 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | suppressed |
| Prednisone | Prednisone | 40 | 15 |
| Tivicay | Dolutegravir Sodium | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 38 | 20 |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 13 |
| Amantadine | Amantadine Hcl | 35 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 31 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 27 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Ingrezza | Valbenazine Tosylate | 26 | suppressed |
| Timolol Maleate | Timolol Maleate | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 13 |
| Prazosin Hcl | Prazosin Hcl | 25 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 25 | suppressed |
| Actemra | Tocilizumab | 24 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 20 |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 22 | 22 |
| Restasis | Cyclosporine | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 20 | suppressed |
| Budesonide | Budesonide | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | 11 |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Sevelamer Hcl | Sevelamer Hcl | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Darunavir | Darunavir | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $371.75 · 5 records | TG Therapeutics, Inc. | BRIUMVI, CAPLYTA, Ozempic, Rybelsus, V.A.C.ULTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error